Member Institutions

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery

BOSTON, June 18, 2012 – Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process.

Peptides have long been sought after as therapeutics due to their high specificity — they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders.

National Post, Financial Post spotlight Flybits’ expansion to Tech City, London (U. K.)

June 18, 2012
Susanne Staer
Flybits

The Financial Post and the National Post each ran a feature article June 18, 2012 concerning the United Kingdom’s efforts to attract Canadian-based technology start-ups seeking entrance into European markets.

Flybits, a Mars Innovation spin-off company based on the research of Ryerson University professor Hossein Rahnama, was among those profiled.

The Accelerator Gazette Interviews Dr. Hossein Rahnama About Student Entrepreneurship

June 14, 2012
Susanne Staer
Flybits

Ryerson University, one of MaRS Innovation’s 16 member institutions, has created the Digital Media Zone (DMZ) to give student entrepreneurs and researchers — or anyone connected with a great idea connected to their campus — the space they need to grow their ideas.

Dr. Hossein Rahnama, the DMZ’s research director and a Ryerson University professor, was interviewed this week by The Accelerator Gazette about Ryerson’s approach to accelerating and incubating technologies.

University of Toronto: Snapshot of Toronto’s Entrepreneurship Scene

The University of Toronto’s news site has posted a brief snapshot of Toronto’s entrepreneurial scene, highlighting the university’s historical and current innovative strengths.

Here’s a brief excerpt:

Entrepreneurs don’t have to be in Silicon Valley to become the next great business success story. Toronto now ranks fourth among the world’s top 25 start-up ecosystems, according to Start-up Genome, a project that maps the success rates of start-ups. Toronto ranks just behind Silicon Valley, New York City and London.

ScarX Therapeutics Featured on Front Page of the Globe and Mail

MaRS Innovation’s ScarX Therapeutics, a strategic partnership with The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek), was featured on the front page of the Globe and Mail on May 7, 2010.

Read the article on Globe and Mail.com (note that depending on when you’re accessing this page, the Globe‘s content may be subject to a pay wall).

MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China

MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek) have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery.

This project was covered in The Globe and Mail on May 7, 2012.

ApneaDX Inc: A Medical Device to Accurately Diagnose Sleep Apnea at Home

April 27, 2012
Susanne Staer
BresoTec Inc.

MaRS Innovation and the University Health Network‘s Toronto Rehabilitation Institute have collaborated to bring a new technology to market that accurately diagnoses sleep apnea at the patient’s home.

Sleep apnea is a medical disorder that is gaining increasing recognition as a major health issue. It is estimated that six to eight per cent of the world’s population suffer from the disease, but 85 per cent are undiagnosed.

Undiagnosed sleep apnea is estimated to cause $3.4 billion in additional medical costs in the US.

Xagenic Raises $10 million in Series A Financing

TORONTO (January 30, 2012) – Xagenic Inc., a start-up company created by Dr. Shana Kelley, in partnership with MaRS Innovation, today reached a significant milestone by successfully completing series A financing totaling $10 million.

The financing comes from sources from the private and public sector including CTI Life Sciences Fund L.P., Qiagen N.V. and the Ontario Capital Growth Corporation through its Emerging Technologies Fund.

Encycle investigators receive CQDM investment

CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor

Toronto, December 6, 2011 — The Québec Consortium for Drug Discovery (CQDM) is pleased to announce $1.5 million in funding for two joint Québec/Ontario research projects in biomedical research.

The news was released today at the conference, Connecting Life Sciences Across the Ontario-Québec Corridor, which was held in Toronto.

Prestigious Award: MaRS Innovation Board Member Ilse Treurnicht named one of Canada’s Most Powerful Women

December 1, 2011
Susanne Staer
Awards

MaRS Discovery District and MaRS Innovation congratulate CEO Dr. Ilse Treurnicht for being recognized as one of Canada’s top 100 female achievers in the private, public and not-for-profit sectors.

For a second time, Dr. Treurnicht has been honoured with the prestigious Canada’s Most Powerful Women: Top 100™. Award in the Trailblazers & Trendsetters category. Her first Top 100™ win was announced in 2009.

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

National Post, Financial Post spotlight Flybits’ expansion to Tech City, London (U. K.)

The Accelerator Gazette Interviews Dr. Hossein Rahnama About Student Entrepreneurship

University of Toronto: Snapshot of Toronto’s Entrepreneurship Scene

ScarX Therapeutics Featured on Front Page of the Globe and Mail

MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China

ApneaDX Inc: A Medical Device to Accurately Diagnose Sleep Apnea at Home

Xagenic Raises $10 million in Series A Financing

Encycle investigators receive CQDM investment

Prestigious Award: MaRS Innovation Board Member Ilse Treurnicht named one of Canada’s Most Powerful Women

Quick Links

Contact Us